J Drugs Dermatol. 2021 Aug 1;20(8):901-904. doi: 10.36849/JDD.6175.
Anti-epidermal growth factor receptor (EGFR) antibodies and anti-programmed cell death 1 protein (PD-1) antibodies have been used separately to treat metastatic cutaneous squamous cell carcinoma (cSCC). While two anti-EGFR antibodies have similar clinical activity, cetuximab is administered weekly, whereas panitumumab is administered every two weeks. This report details findings using panitumumab in combination with anti-PD-1 antibody in patients with relapsed refractory cSCC. Three consecutive patients with poor performance status and rapidly progressive recurrent cutaneous squamous cell carcinoma (cSCC) of the face or scalp signed informed consent to receive an anti-PD-1 antibody with the option to add panitumumab were there inadequate response. After 2, 5, and 7 cycles of anti-PD-1 antibody treatment, respectively, panitumumab was added and the combination was continued for 27, 7, and 5 cycles, respectively. Fatigue, rash, and hypomagnesemia were reported, consistent with expectations for either agent alone. All three patients achieved durable complete response. The favorable clinical outcomes support further evaluation of the combination of anti-PD1 and anti-EGFR antibodies to control refractory cSCC of the face or scalp. J Drugs Dermatol. 2021;20(8):901-904. doi:10.36849/JDD.6175.
抗表皮生长因子受体 (EGFR) 抗体和抗程序性死亡蛋白 1 抗体 (PD-1) 抗体已分别用于治疗转移性皮肤鳞状细胞癌 (cSCC)。虽然两种抗 EGFR 抗体具有相似的临床活性，但西妥昔单抗每周给药一次，而帕尼单抗每两周给药一次。本报告详细介绍了在复发难治性 cSCC 患者中使用帕尼单抗联合抗 PD-1 抗体的发现。连续 3 名患者表现出较差的身体状况和快速进展的复发性面部或头皮皮肤鳞状细胞癌 (cSCC)，他们签署了知情同意书，选择接受抗 PD-1 抗体治疗，如果反应不足，可以选择添加帕尼单抗。在分别接受 2、5 和 7 个周期的抗 PD-1 抗体治疗后，分别添加了帕尼单抗，并分别继续接受 27、7 和 5 个周期的联合治疗。报告了疲劳、皮疹和低镁血症，与单独使用任何一种药物的预期一致。所有 3 名患者均获得了持久的完全缓解。良好的临床结果支持进一步评估抗 PD1 和抗 EGFR 抗体联合治疗以控制面部或头皮难治性 cSCC。J 皮肤病学杂志。2021;20(8):901-904. doi:10.36849/JDD.6175.
